1
|
Oliver Metzig M, Tang Y, Mitchell S, Taylor B, Foreman R, Wollman R, Hoffmann A. An incoherent feedforward loop interprets NFκB/RelA dynamics to determine TNF-induced necroptosis decisions. Mol Syst Biol 2020; 16:e9677. [PMID: 33314666 PMCID: PMC7734648 DOI: 10.15252/msb.20209677] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 10/23/2020] [Accepted: 10/26/2020] [Indexed: 12/31/2022] Open
Abstract
Balancing cell death is essential to maintain healthy tissue homeostasis and prevent disease. Tumor necrosis factor (TNF) not only activates nuclear factor κB (NFκB), which coordinates the cellular response to inflammation, but may also trigger necroptosis, a pro-inflammatory form of cell death. Whether TNF-induced NFκB affects the fate decision to undergo TNF-induced necroptosis is unclear. Live-cell microscopy and model-aided analysis of death kinetics identified a molecular circuit that interprets TNF-induced NFκB/RelA dynamics to control necroptosis decisions. Inducible expression of TNFAIP3/A20 forms an incoherent feedforward loop to interfere with the RIPK3-containing necrosome complex and protect a fraction of cells from transient, but not long-term TNF exposure. Furthermore, dysregulated NFκB dynamics often associated with disease diminish TNF-induced necroptosis. Our results suggest that TNF's dual roles in either coordinating cellular responses to inflammation, or further amplifying inflammation are determined by a dynamic NFκB-A20-RIPK3 circuit, that could be targeted to treat inflammation and cancer.
Collapse
Affiliation(s)
- Marie Oliver Metzig
- Signaling Systems LaboratoryDepartment of MicrobiologyImmunology and Molecular GeneticsUCLALos AngelesCAUSA
- Institute for Quantitative and Computational BiosciencesUCLALos AngelesCAUSA
| | - Ying Tang
- Signaling Systems LaboratoryDepartment of MicrobiologyImmunology and Molecular GeneticsUCLALos AngelesCAUSA
- Institute for Quantitative and Computational BiosciencesUCLALos AngelesCAUSA
| | - Simon Mitchell
- Signaling Systems LaboratoryDepartment of MicrobiologyImmunology and Molecular GeneticsUCLALos AngelesCAUSA
- Institute for Quantitative and Computational BiosciencesUCLALos AngelesCAUSA
- Present address:
Brighton and Sussex Medical SchoolUniversity of SussexBrightonUK
| | - Brooks Taylor
- Signaling Systems LaboratoryDepartment of MicrobiologyImmunology and Molecular GeneticsUCLALos AngelesCAUSA
- Institute for Quantitative and Computational BiosciencesUCLALos AngelesCAUSA
| | - Robert Foreman
- Institute for Quantitative and Computational BiosciencesUCLALos AngelesCAUSA
- Department of Chemistry and BiochemistryUCLALos AngelesCAUSA
- Department of Integrative Biology and PhysiologyUCLALos AngelesCAUSA
| | - Roy Wollman
- Institute for Quantitative and Computational BiosciencesUCLALos AngelesCAUSA
- Department of Chemistry and BiochemistryUCLALos AngelesCAUSA
- Department of Integrative Biology and PhysiologyUCLALos AngelesCAUSA
| | - Alexander Hoffmann
- Signaling Systems LaboratoryDepartment of MicrobiologyImmunology and Molecular GeneticsUCLALos AngelesCAUSA
- Institute for Quantitative and Computational BiosciencesUCLALos AngelesCAUSA
| |
Collapse
|
2
|
O'Shea P, Wildenhain J, Leveridge M, Revankar C, Yang JP, Bradley J, Firth M, Pilling J, Piper D, Chesnut J, Isherwood B. A Novel Screening Approach for the Dissection of Cellular Regulatory Networks of NF-κB Using Arrayed CRISPR gRNA Libraries. SLAS DISCOVERY : ADVANCING LIFE SCIENCES R & D 2020; 25:618-633. [PMID: 32476557 DOI: 10.1177/2472555220926160] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
CRISPR/Cas9 is increasingly being used as a tool to prosecute functional genomic screens. However, it is not yet possible to apply the approach at scale across a full breadth of cell types and endpoints. In order to address this, we developed a novel and robust workflow for array-based lentiviral CRISPR/Cas9 screening. We utilized a β-lactamase reporter gene assay to investigate mediators of TNF-α-mediated NF-κB signaling. The system was adapted for CRISPR/Cas9 through the development of a cell line stably expressing Cas9 and application of a lentiviral gRNA library comprising mixtures of four gRNAs per gene. We screened a 743-gene kinome library whereupon hits were independently ranked by percent inhibition, Z' score, strictly standardized mean difference, and T statistic. A consolidated and optimized ranking was generated using Borda-based methods. Screening data quality was above acceptable limits (Z' ≥ 0.5). In order to determine the contribution of individual gRNAs and to better understand false positives and negatives, a subset of gRNAs, against 152 genes, were profiled in singlicate format. We highlight the use of known reference genes and high-throughput, next-generation amplicon and RNA sequencing to assess screen data quality. Screening with singlicate gRNAs was more successful than screening with mixtures at identifying genes with known regulatory roles in TNF-α-mediated NF-κB signaling and was found to be superior to previous RNAi-based methods. These results add to the available data on TNF-α-mediated NF-κB signaling and establish a high-throughput functional genomic screening approach, utilizing a vector-based arrayed gRNA library, applicable across a wide variety of endpoints and cell types at a genome-wide scale.
Collapse
Affiliation(s)
- Patrick O'Shea
- Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | | | - Mathew Leveridge
- Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | | | | | - Jenna Bradley
- Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - Mike Firth
- Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | - James Pilling
- Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| | | | | | - Beverley Isherwood
- Discovery Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
| |
Collapse
|